News
Tue 19 Nov 2024
AI for plants based drug discovery: Kantify lecture at IBMCP
How can AI accelerate target discovery and small molecule discovery in plants? First lecture at IBMCP
Tue 19 Nov 2024
Kantify announced as speaker at BioFIT 2024
Kantify will be speaking at the BioFIT event
Thu 22 Aug 2024
DREAMS: when AI finds drugs for rare diseases
Discover on the DREAMS project website how Kantify contributes to the discovery of therapeutic targets and treatments for 5 rare neuromuscular disorders
Tue 30 Jul 2024
AI unveils secret targets of drugs, starting with Viagra
In a new White Paper, Kantify presents its AI powered Drug Atlas and unveils the predicted targets for Sildenafil (Viagra)
Wed 24 Jul 2024
A new name for the Kantify AI platform for drug discovery
Kantify shares the new name for its AI platform for small molecule and target discovery
Thu 11 Jul 2024
Kantify to speak at Science for Health
Join us at Science for Health, the flagship event Biology meets technology: AI, Data & Digitalization
Tue 30 Apr 2024
New poster on AI for drug discovery for muscular dystrophies
At Myology 2024, Emilie PELLIER & Quentin MIAGOUX from i-Stem presented our collaboration on AI powered target and drug discovery for LGMDR2
Tue 02 Apr 2024
Kantify reveals promising results in sarcoma at ESMO
Kantify Unveiled Promising Results in Liposarcoma Drug Discovery thanks to AI at ESMO Sarcoma and Rare Cancer Congress 2024
Tue 19 Mar 2024
Nicolas Maignan appointed Chief Operating Officer of Kantify
Announcement: Nicolas Maignan is officially appointed COO of Kantify
Thu 14 Mar 2024
AI for Healthcare panel at the Pharma.be General Assembly
Kantify was invited at the pharma.be special panel on AI for Healthcare
Mon 11 Mar 2024
Poster at ESMO : AI for target and drug discovery in sarcoma
Kantify will share its latest results on rapid identification of novel targets and polypharmacological compounds for liposarcoma treatment, thanks to AI
Mon 11 Dec 2023
Kantify at Belgium's Biopharmaceutical Excellence Conference
Kantify shared some of its groundbreaking work at the Conference on the Belgian biopharmaceutical sector organized by the Federal Ministry of Foreign Affairs